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Focal adhesions are foci for tyrosine-based signal 
transduction via GIV/Girdin and G proteins
Inmaculada Lopez-Sancheza, Nicholas Kalogriopoulosa, I-Chung Lob, Firooz Kabira,  
Krishna K. Middea, Honghui Wangb, and Pradipta Ghosha,b
aDepartment of Medicine and bDepartment of Cellular and Molecular Medicine, University of California, San Diego, 
School of Medicine, La Jolla, CA 92093
ABSTRACT GIV/Girdin is a multimodular signal transducer and a bona fide metastasis-relat-
ed protein. As a guanidine exchange factor (GEF), GIV modulates signals initiated by growth 
factors (chemical signals) by activating the G protein Gαi. Here we report that mechanical 
signals triggered by the extracellular matrix (ECM) also converge on GIV-GEF via β1 integrins 
and that focal adhesions (FAs) serve as the major hubs for mechanochemical signaling via GIV. 
GIV interacts with focal adhesion kinase (FAK) and ligand-activated β1 integrins. Phosphoryla-
tion of GIV by FAK enhances PI3K-Akt signaling, the integrity of FAs, increases cell–ECM ad-
hesion, and triggers ECM-induced cell motility. Activation of Gαi by GIV-GEF further potenti-
ates FAK-GIV-PI3K-Akt signaling at the FAs. Spatially restricted signaling via tyrosine 
phosphorylated GIV at the FAs is enhanced during cancer metastasis. Thus GIV-GEF serves as 
a unifying platform for integration and amplification of adhesion (mechanical) and growth 
factor (chemical) signals during cancer progression.
INTRODUCTION
The protein Gα-interacting, vesicle-associated (GIV; also known as 
Girdin) is a bona fide metastasis-related protein and a guanidine 
exchange factor (GEF) for trimeric Gi proteins that serves as a hub 
for enhancement of phosphoinositide 3-kinase (PI3K)-Akt signals 
(Garcia-Marcos et al., 2015). Ligand stimulation of a variety of recep-
tors directly (e.g., growth factor receptor tyrosine kinases [RTKs]; 
Ghosh, 2015) or indirectly via non-RTKs (e.g., G protein–coupled 
receptors [GPCRs] and Toll-like receptors [TLRs]) triggers phosphor-
ylation of GIV on two key tyrosines (Y1764 and Y1798) within its C-
terminus, which directly bind and activate class 1 PI3Ks (Lin et al., 
2011). GIV-dependent PI3K-Akt enhancement regulates a range of 
pathophysiologic processes in diverse cell types, including cancer 
metastasis across a variety of solid tumors (Garcia-Marcos et al., 
2015), epithelial wound healing (Ghosh et al., 2008), macrophage 
chemotaxis (Ghosh et al., 2008), myofibroblast activation during or-
gan fibrosis (Lopez-Sanchez et al., 2014), podocyte survival after 
nephrotic injury (Wang et al., 2015), and insulin sensitivity in myo-
blasts (Hartung et al., 2013).
Mechanistically, GIV affects the aforementioned processes by 
modulating multi-RTK signaling at the plasma membrane (PM) via G 
protein intermediates, which in turn enhances tyrosine-based sig-
naling through the RTK-GIV-PI3K axis (Ghosh, 2015; Lin et al., 2011, 
2014). Despite these insights, the spatial configuration of such acti-
vated receptor–GIV signaling clusters remains unknown. Here we 
report that these activated signaling clusters predominantly localize 
to specialized concentrated patches at the PM called focal adhe-
sions (FAs), which are mechanical sensors of environmental forces 
via integrins. Novel functional interactions with components of the 
FA enable GIV to serve as a common platform for both chemical 
sensing by RTKs and mechanosensing via integrins. Findings also 
illuminate how GIV’s functions at the FAs may facilitate its widely 
recognized role in cancer metastasis.
RESULTS AND DISCUSSION
GIV localizes to FAs and is required for their integrity
We previously showed that GIV modulates growth factor RTK sig-
naling via its ability to bind ligand-activated RTKs and couple them 
to activation of G proteins at the PM (Midde et al., 2015). To study 
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FIGURE 1: GIV localizes to FAs and is essential for the integrity of these structures. (A, B) Cos7 cells grown on collagen-
coated coverslips were fixed and costained with GIV (green), vinculin (red), and DAPI (nuclei; blue; A) or with vinculin 
(green), phalloidin–Texas red (F-actin, red), and DAPI (nuclei; blue; B) and analyzed by confocal microscopy. 
Representative images. Bar, 10 μm. (C) Cos7 cells grown on either noncoated (left) or collagen-coated (right) glass 
coverslips, fixed, and costained with phospho-Tyr-1764-GIV (pYGIV; red), vinculin (green), and DAPI (nuclei; blue) and 
analyzed by confocal microscopy. Arrowheads indicated focal complexes; arrows indicate mature FAs. Representative 
images. Bar, 10 μm. (D) Cos7 cells were fixed and costained with phospho-Tyr-1764-GIV (pYGIV; green), phalloidin–Texas 
red (F-actin; red), paxillin (far red; pseudocolored purple), and DAPI (nuclei; blue) and analyzed by 
Volume 26 December 1, 2015 GIV-GEF modulates integrin signaling | 4315 
sines on GIV that were previously shown to directly bind Src-homol-
ogy 2 domains of p85α (PI3K) and activate the p110 (PI3K) catalytic 
subunit (Lin et al., 2011). FAK also phosphorylated GIV in cells be-
cause expression of the wild type but not the kinase-dead mutant 
FAK(K454R) in Cos7 cells triggered tyrosine phosphorylation of GIV 
(Figure 2B) and pharmacologic inhibition of FAK abolished tyrosine 
phosphorylation of GIV (Figure 2C). Immunofluorescence on Cos7 
cells undergoing adhesion on collagen-coated surface showed that 
by 30 min, active FAK, as determined by phosphorylation of Y397 
(Chen et al., 1996), and active pYGIV colocalized extensively within 
nascent FAs at the cell periphery (Figure 2D). By 4 h, extensive colo-
calization was maintained but shifted to mature FAs (Figure 2D). 
Whereas ∼50% of the cells showed pYGIV labeling of nascent FAs at 
the cell periphery without paxillin in those structures, the reverse 
(i.e., paxillin-labeled structures devoid of pYGIV) was never encoun-
tered (Supplemental Figure S1F). Thus the localization of active pY-
GIV to FAs coincided temporospatially with activated FAK and pre-
ceded the localization of paxillin to FAs. 
Next we asked whether GIV and FAK interact in cells by perform-
ing proximity ligation assays (PLAs) to detect in situ active GIV-FAK 
complexes in Cos7 cells. PLA signals were detected between en-
dogenous active GIV and FAK (Figure 2E and Supplemental Figure 
2SA), indicating that they interact (i.e., the maximum distance be-
tween the two is ≤30–40 nm; Soderberg et al., 2006). Taken to-
gether, these findings indicate that FAK binds and phosphorylates 
GIV and that such phosphoevents occur during the early stages of 
cell–extracellular matrix (ECM) adhesion within FAs, before paxillin is 
enriched at those locations. These observations are in keeping with 
the previously reported temporal and spatial dynamics of FAK activ-
ity during cell adhesion (Serrels and Frame, 2012). Because GIV is 
also a substrate of multiple RTKs and the non-RTK Src (Lin et al., 
2011) and those TKs also phosphorylate substrates within FAs, how 
much of the observed active pool of pYGIV at the FAs is a direct 
contribution of FAK remains to be determined.
Tyrosine phosphorylation of GIV is required for 
enhancement of PI3K-Akt signals, integrity of FAs, 
cell adhesion, and haptotaxis
To analyze the role of tyrosine phosphorylation of GIV in signaling at 
the FAs, we rescued Cos7 cells that were depleted of endogenous 
GIV by stably expressing FLAG-tagged wild-type (WT) or various 
GIV mutants (YF, nonphosphorylatable; FA, GEF deficient; YF/FA, 
combination of both; Supplemental Figure S2, B and C). First we 
asked whether FAK enhances PI3K/Akt signaling via its substrate 
GIV. We found that the Akt signaling response that was triggered by 
collagen was blunted in cells expressing the nonphosphorylatable 
GIV-YF mutant compared with those expressing GIV-WT (Figure 2F). 
Compared to Cos7 cells expressing GIV-WT, GIV-YF cells also 
showed fewer FAs (∼75% reduction; Figure 2, G and H), as deter-
mined by immunofluorescence for vinculin and paxillin, impaired 
cell–ECM adhesion (∼45% reduction; Figure 2I), and reduced colla-
gen-induced motility (∼40% reduction; Figure 2J and Supplemental 
specifically the localization of GIV at the PM without the noise con-
tributed by the larger cytosolic pool, we carried out immunofluores-
cence studies on cells fixed using a low-temperature methanol-fixa-
tion treatment that leads to improved accessibility of the intracellular 
antigens and reduces cytosolic background (Schnell et al., 2012). 
GIV localized to the Golgi, the nucleus, and actin stress fibers (Figure 
1A), all previously reported by us and others (Enomoto et al., 2005; 
Ghosh et al., 2008). A pool of actin-bound GIV colocalized with vin-
culin, indicating that GIV localizes also on PM patches where actin 
caps associate with FAs (Figure 1B); this pattern is specific, because 
it was lost in GIV-depleted cells (Supplemental Figure S1A). When 
we immunostained for the tyrosine-phosphorylated pool of “active” 
GIV (pYGIV), as determined by a diagnostic-grade antibody previ-
ously validated and confirmed to specifically detect phospho-Tyr-
1764-GIV (see Materials and Methods), we found it to be almost 
exclusively colocalized with vinculin in FAs: in the absence of colla-
gen, pYGIV and vinculin colocalized predominantly in the peripher-
ally located “environment-probing” focal complexes (Figure 1C, 
left), whereas in the presence of collagen, they colocalized primarily 
within mature FAs (Figure 1C, right). Localization of GIV at FAs was 
further confirmed using paxillin, another marker of FAs (Figure 1D 
and Supplemental Figure S1B). Finally, tyrosine-phosphorylated GIV 
localized to FAs in cells stimulated exclusively with collagen in the 
absence of serum (Supplemental Figure S1C), suggesting that inte-
grin signaling is sufficient for both tyrosine phosphorylation and lo-
calization of GIV at FAs. These results indicate that a pool of total 
GIV and the majority of “active” pYGIV localize discretely to nascent 
and mature FAs (Figure 1E).
To determine the role of GIV at FAs, we analyzed GIV-depleted 
Cos7 cells (∼85% depletion efficacy by short hairpin RNA [shRNA]; 
Supplemental Figure S1D) and found that, compared with controls, 
these cells had fewer FA structures (by ∼80%, as determined by 
quantification of structures that immunostained for vinculin and pax-
illin [Figure 1, F and G] using the particle analyzer feature of ImageJ; 
Horzum et al., 2015) and impaired collagen-induced motility (∼40% 
reduction, as determined using Transwell haptotactic cell motility 
assays [Figure 1H and Supplemental S1E]). We conclude that GIV is 
an essential functional component within the FAs.
GIV is a substrate of focal adhesion kinase 
Because tyrosine-phosphorylated GIV is primarily restricted to FAs 
(Figure 1), we asked whether GIV is a substrate of the non-RTK focal 
adhesion kinase (FAK), a key component of the signal transduction 
pathways triggered by integrins whose activity is restricted to the 
FAs (Sulzmaier et al., 2014). In vitro kinase assays on the histidine 
(His)-tagged C-terminus of GIV (GIV-CT) showed that such is indeed 
the case; GIV was phosphorylated at two critical sites, Tyr (Y)-1764 
and -1798, by recombinant FAK, and no phosphorylation was ob-
served using a mutant in which both tyrosines were replaced with 
Phe (YF; Figure 2A). Because the commercially obtained FAK used 
in these assays was purified from insect cells to >95% purity, we 
conclude that FAK phosphorylates GIV; it targets the two key tyro-
confocal microscopy. Representative images are shown. Bar, 25 μm. (E) Schematic summarizing the findings in A–D.  
(F, G) Control (sh Control) or GIV-depleted (sh GIV) Cos7 cells were fixed and stained for vinculin (red, F) or paxillin  
(red, G) and DAPI (nuclei; blue) and analyzed by confocal microscopy. In GIV-depleted cells we found that vinculin was 
present on vesicular structures (arrowheads). Representative images are shown. Bar, 25 μm. Depletion of GIV was 
confirmed by immunoblotting (Supplemental Figure S1D). (H) Cos7 cells in F and G were analyzed for collagen-induced 
haptotactic cell motility using Transwell assays. Bar graphs show quantification of the number of migrated cells/
high-power fields (HPF). Error bars represent mean ± SD; n = 3; *p < 0.05.
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FIGURE 2: Phosphorylation of GIV by FAK is required for cell–ECM adhesion and collagen-induced haptotaxis. (A) In 
vitro kinase assays were carried out with recombinant FAK and equal aliquots of either WT or mutant His-GIV-CT 
(aa 1660–1870) proteins. Phosphorylated GIV was detected by immunoblotting using anti–phospho-Tyr antibody (top; 
green). His-GIV-CT proteins were visualized using GIV-CT antibody (middle; red). Yellow pixels in the merged panel 
represent tyrosine-phosphorylated GIV-CT. (B) Cos7 cells expressing control vector, wild-type FAK (myc-FAK-WT), or a 
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W258F mutant of Gαi3, henceforth referred to as Gαi3-WF, in Cos7 
cells; the latter cannot bind or be activated by GIV but localizes and 
interacts with Gβγ, GPCRs, and Gαi regulators similarly to Gαi3-WT 
(Garcia-Marcos et al., 2010). Compared to cells expressing Gαi3-WT, 
those expressing Gαi3-WF exhibited similar defects as observed in 
cells expressing GIV-FA; the number of FAs was reduced (by ∼43%), 
as determined by staining for vinculin (Figure 3E and Supplemental 
Figure S3B) and FAK activation (Figure 3F and Supplemental Figure 
S3C), and phosphorylation of GIV (Supplemental Figure S3D) at the 
FAs were impaired. These results obtained using well-characterized 
and specific GIV (FA) and Gαi3 (WF) mutants that selectively block 
GIV’s ability to bind and activate the G protein demonstrate that acti-
vation of Gi by GIV is key for maximal enhancement of FAK activity for 
the functional integrity of FAs during chemotaxis toward collagen.
Our findings are in keeping with previous studies that showed 
not only that G proteins localize to FAs (Hansen et al., 1994; Buhl 
et al., 1995; Ueda et al., 1997) and are active at that location (Gong 
et al., 2010), but also that Gαi activation by GPCRs affects FAK activ-
ity (Thennes and Mehta, 2012). We conclude that noncanonical Gi 
activation by the nonreceptor GEF GIV also affects the integrity of 
FAs, in part via enhancement of FAK activity.
GIV colocalizes with and binds ligand-activated β1 integrins
Next we asked whether active GIV colocalizes with integrins and 
specifically examined β1 integrins, a major subunit of collagen I–
binding integrins (Jokinen et al., 2004). Immunofluorescence stud-
ies confirmed that both total (Figure 4A) and active pYGIV (Figure 4B) 
colocalized with integrin clusters, as well as with bundles of β1 inte-
grin, within 10 min after acute stimulation with collagen and contin-
ued to show more prominent colocalization at 30 min and 2 h (un-
published data).
Because several adaptors serve as mechanotransducers by di-
rectly binding to β-integrin cytoplasmic tails (Legate and Fassler, 
2009) and GIV couples G proteins to a variety of receptors (Garcia-
Marcos et al., 2015; Midde et al., 2015), next we asked whether GIV 
and Gαi interact with integrins. We found that both GIV and Gαi3 
coimmunoprecipitate with β1 integrin exclusively after stimulation 
Figure S2D). These findings indicate that tyrosine phosphorylation 
of GIV is an essential step for the maximal activation of PI3K-Akt 
signals by FAK and for the functional integrity of FAs. Because phos-
phosites generated by FAK at tyrosines 1764 and 1798 on GIV can 
directly bind and activate PI3K (Lin et al., 2011), we conclude that 
GIV, a bona fide PI3K/Akt-enhancer (Lin et al., 2011), is a key sub-
strate of FAK that enhances PI3K-Akt signals in response to ECM.
Activation of Gαi by GIV enhances FAK activity 
and collagen-induced haptotaxis
Because GIV modulates signaling pathways by activating G proteins 
(Garcia-Marcos et al., 2015), next we asked how activation of Gi by 
GIV-GEF affects the integrity of FAs. We found that loss of FAs in 
GIV-depleted Cos7 cells was rescued by GIV-WT but not the GEF-
deficient F1685A mutant of GIV (GIV-FA; Figure 3A and Supplemen-
tal Figure S3A); the latter cannot bind or activate Gαi (Garcia-Mar-
cos et al., 2009). The cells expressing GIV-FA adhered as efficiently 
as those expressing GIV-WT in low serum (Figure 2I) but were disad-
vantaged in the presence of 10% serum (Figure 3B) and showed 
reduced haptotactic motility toward collagen (Figure 2J and 
Supplemental Figure S2D). As for the mechanism for such impaired 
haptotaxis, we found that activation of Akt was reduced in cells ex-
pressing GIV-FA (Figure 2F). This is in keeping with the fact that 
GIV’s GEF function enhances PI3K/Akt signals via “free” Gβγ-
intermediates (Garcia-Marcos et al., 2009) and, together with GIV’s 
phosphotyrosines, maximally enhances Akt signaling in an “AND 
gate” mode (Lin et al., 2011), that is, both GEF and phosphotyro-
sines are required for maximal signaling. In addition, in cells ex-
pressing GIV-FA (Figure 3C) or depleted of GIV (Figure 3D), colla-
gen-stimulated FAK activity, as determined by phosphorylation at 
Tyr-397 was also suppressed. Consistent with reduced activation of 
FAK, phosphorylation of its substrate, GIV at Tyr-1764 was similarly 
impaired (Figure 3A and Supplemental Figure S3A). Thus the GEF 
motif via which GIV activates Gαi is essential to maintain FA integ-
rity, FAK and PI3K/Akt signaling, and collagen-induced chemotaxis.
The role of Gαi activation by GIV-GEF was further analyzed by 
expressing either wild-type (Gαi3-WT) or a dominant-negative 
kinase-dead mutant FAK (myc-FAK-KD) were analyzed by immunoblotting for phosphorylation of endogenous GIV 
using anti–phospho-Tyr-1764-GIV (pYGIV) antibody. Expression of FAK (myc), Gαi3, and tubulin was analyzed by 
immunoblotting. (C) Cos7 cells were grown on culture dishes coated with poly-d-lysine, treated with FAK inhibitor 14 
(FAK-Inh-14) or vehicle (dimethyl sulfoxide [DMSO]) for 24 h, and then seeded on collagen-coated dishes for 1 h before 
lysis and analyzed for total (t) and phosphoproteins (p) by immunoblotting (IB). (D) Cos7 cells were acutely stimulated 
with collagen before fixation (see Materials and Methods) and stained with phospho–Tyr-1764-GIV (pYGIV; green), 
phospho–Tyr-397-FAK (pYFAK; red), and DAPI (nuclei; blue) and analyzed by confocal microscopy. Bar, 25 μm. (E) Cos7 
cells were analyzed for interaction between active pYGIV and active pYFAK by in situ PLA using rabbit anti-pYGIV and 
mouse anti-pYFAK antibodies. Red dots indicate sites of interaction. Incubation with secondary antibodies alone or with 
paxillin antibody showed no signal (negative controls; Supplemental Figure S2A). Bar, 25 μm. (F) GIV-depleted Cos7 
cells stably expressing FLAG-tagged WT or mutant GIV constructs were grown on culture dishes coated with poly-d-
Lysine (P) and then seeded on collagen-coated (C) dishes for 1 h before lysis and analyzed for phospho (p-) and total (t-) 
Akt by immunoblotting (IB). Compared to GIV-WT cells, percentage phosphorylation of Akt was suppressed by 65% in 
GIV-YF cells, 82% in GIV-FA cells, and 73% in GIV-YF/FA cells (p < 0.001), as determined by band densitometry using 
LiCOR Odyssey. (G, H) GIV-depleted (sh GIV) Cos7 cells stably expressing GIV-WT or GIV-YF mutant were fixed and 
stained for phospho–Tyr-1764-GIV (pYGIV; green), vinculin (red), and DAPI (nuclei; blue; G) or for paxillin (red, shown in 
grayscale; H) and analyzed by confocal microscopy. Bar, 25 μm. (I) Colorimetric adhesion assays were carried out using 
control (sh Control), GIV-depleted (sh GIV), or GIV-depleted cells stably expressing various GIV constructs in media with 
low serum. Error bars represent mean ± SD; n = 3; **p < 0.01; ***p < 0.001; n.s, not significant. See also Supplemental 
Figure S2, B and C, for immunoblots showing the levels of GIV expression and other FA proteins in these cell lines. 
(J) Cells in I were analyzed for collagen-induced haptotactic cell motility using Transwell assays. Images of 
representative fields are displayed in Supplemental Figure S2D. Bar graphs show quantification of the number of cells 
that migrated averaged from ∼ 20 high-power field-of-view images per experiment. Error bars represent mean ± SD; 
n = 3; *p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 3: Activation of Gαi by GIV’s GEF motif enhances FAK activity, the integrity of FAs, and cell–ECM adhesion. 
(A) GIV-depleted Cos7 cells stably expressing GIV-WT, GIV-FA, or GIV-YF/FA were fixed and stained for phospho–Tyr-
1764-GIV (pYGIV; green), vinculin (red), and DAPI (nuclei; blue) and analyzed by confocal microscopy. Bar, 25 μm. 
(B) Colorimetric cell adhesion assay was carried out using control (sh Control), GIV-depleted (sh GIV) Cos7 cells, or those 
stably expressing GIV-WT or various mutants in the presence of 10% FBS. Error bars represent mean ± SD; n = 3; 
**p < 0.01, ***p < 0.001, ****p < 0.0001. (C) GIV-depleted Cos7 cells stably expressing GIV-WT or GIV-FA were fixed 
and stained for phospho–Tyr-397-FAK (pYFAK; shown in grayscale) and analyzed by confocal microscopy. Boxed areas 
are magnified and displayed as insets. Bar, 25 μm. (D) Control (sh Control) or GIV-depleted (sh GIV) Cos7 cells were 
fixed and stained for phospho–Tyr-397-FAK (pYFAK; shown in grayscale) as in C. Bar, 25 μm. (E) Cos7 cells transfected 
with internally tagged Gαi3-WT-CFP (cyan; left) or Gαi3-WF-CFP (cyan; right) were fixed and stained for vinculin (red) 
and analyzed by confocal microscopy. The red channel (vinculin) in the boxed areas is magnified and displayed in 
grayscale as inset. Individual channels are shown in Supplemental Figure S3B. Bar, 25 μm. (F) Cos7 cells in E were 
stained for pYFAK (red) and analyzed by confocal microscopy. Expression of Gαi3-WF reduced the intensity of pYFAK at 
FA structures by ∼72%. The red channels (pYFAK) in the boxed areas are magnified and displayed in grayscale as inset. 
Individual channels are shown in Supplemental Figure S3C. Bar, 25 μm.
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FIGURE 4: GIV colocalizes with bundles of β1 integrins and couples G proteins to β1 integrins. (A, B) HeLa cells grown 
on a poly-d-lysine–coated surface were resuspended, plated on collagen-coated surface for ∼10 min, fixed, stained for 
β1 integrin (green), DAPI (nuclei; blue), and either GIV (red; A) or pYGIV (red; B) and analyzed by confocal microscopy. 
A line scan plot of relative fluorescence intensities of β1 integrin and GIV in A was analyzed using the RGB profiler 
plug-in from Image J. Bar, 25 μm. (C) HeLa cells grown on poly-d-lysine were stimulated (+) or not (–) with collagen and 
lysed, and the lysates were subjected to immunoprecipitation using anti–β1 integrin antibody. Immune complexes were 
analyzed for GIV, β1 integrin, and Gα3 by immunoblotting. (D) Schematic illustration summarizing how GIV-GEF 
modulates tyrosine-based and G protein signaling in the vicinity of ligand-activated β1 integrins.
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purchased from Invitrogen (Carlsbad, CA). Recombinant FAK protein 
was purchased from SignalChem (Richmond, Canada). FAK inhibitor 
14 was purchased from Santa Cruz Biotechnology (Dallas, TX). All 
restriction endonucleases and Escherichia coli strain DH5α were pur-
chased from New England Biolabs (Ipswich, MA). E. coli strain BL21 
(DE3) and phalloidin–Texas red were purchased from Invitrogen. 
4′,6-Diamidino-2-phenylindole (DAPI) was purchased from Molecular 
Probes (Invitrogen). Genejuice transfection reagent was obtained 
from Novagen (EMD Millipore; San Diego, CA) and TransIT-LT1 from 
Mirus Bio LLC (Madison, WI). Rat-tail collagen I was obtained from 
BD Biosciences and poly-d-lysine from Sigma-Aldrich. Puromycin was 
purchased from Life Technologies (Carlsbad, CA) and neomycin ana-
logue G418 from Cellgro (Manassas, VA). Paraformaldehyde (PFA) 
16% was purchased from Electron Microscopy Sciences.
Mouse monoclonal antibodies against Akt and β-tubulin and 
rabbit polyclonal antibodies against the last 18 amino acids (aa) of 
the C-terminus of GIV (GIV-CT, T-13), total FAK, β1 integrin (for im-
munoblotting and immunoprecipitation only), Gαi3 (M-14), and 
GFP were obtained from Santa Cruz Biotechnology. Rabbit antibody 
against phospho–Akt-Ser-473 was obtained from Cell Signaling 
(Beverly, MA). Mouse anti-vinculin, FLAG (M2), and polyhistidine 
were obtained from Sigma-Aldrich and anti–phospho-Tyr, phospho–
FAK-Tyr397, and paxillin from BD Transduction Laboratories (San 
Jose, CA). Mouse β1 integrin antibody for immunofluorescence 
studies was obtained from Abcam (Cambridge, MA). Rabbit anti–
GIV coiled-coil (GIV cc) was obtained from Millipore (San Diego, 
CA). The anti–phospho-GIV-Tyr-1764 rabbit monoclonal antibody 
(SP-158) of diagnostic grade was generated collaboratively with 
Ventana (a branch of Roche) and Spring Biosciences (Pleasanton, 
CA). Prior studies using this antibody confirmed that it specifically 
detects GIV phosphorylated at Y1764 but not the dephosphory-
lated protein (Lopez-Sanchez et al., 2014). Goat anti-rabbit and goat 
anti-mouse Alexa Fluor 680 or IRDye 800 F(ab′)2 used for Odyssey 
infrared imaging were from Li-Cor Biosciences (Lincoln, NE). Sec-
ondary goat anti-rabbit or mouse (488), goat anti-rabbit or mouse 
(594), and goat anti-mouse (635) Alexa-conjugated antibodies used 
for immunofluorescence were from Invitrogen (Life Technologies).
Plasmid constructs and protein expression
Cloning of GIV-CT (aa 1660–1870) into pET28b (His-GIV CT) was 
described previously (Garcia-Marcos et al., 2009). For mammalian 
expression, RNA interference–resistant (shRNA rest) GIV was cloned 
into p3XFLAG-CMVTM-14 plasmid (GIV-FLAG) as described previ-
ously (Garcia-Marcos et al., 2009). GIV-FLAG and His-GIV-CT phos-
phomutants (Y1764F, Y1798F, and Y1764/1798F) and GEF-deficient 
mutant (F1685A) were generated by site-directed mutagenesis us-
ing a QuikChange kit (Stratagene) and specific primers (sequence 
available upon request) as per the manufacturer’s protocols (Garcia-
Marcos et al., 2009; Lin et al., 2011). Internally tagged Gαi3-WT-CFP 
was a generous gift from Moritz Bünemann, Philipps-Universität 
Marburg, Marburg, Germany (Bünemann et al., 2003). Gαi3-WF-
CFP mutant (Garcia-Marcos et al., 2010) was generated by site-di-
rected mutagenesis using QuikChange per the manufacturer’s 
protocol. Primer sequences are available upon request. shRNA 
3–untranslated region for GIV (GIV shRNA: CCGGGCTTTCATT ACC
AGCTCTGAACTCGAGTTCAGAGCTGGTAATGAAAGCTTTTTTG) 
was cloned into pLKO.1 (TRCN0000130452) or control vector 
TRC1.5-pLKO.1-puro. pKH3-FAK-WT and pKH3-FAK-K454R were 
generous gifts from Jun-Lin Guan (University of Michigan, Ann 
Arbor, MI).
His-GIV-CT fusion construct was expressed in E. coli strain BL21 
(DE3) and purified as described previously (Ghosh et al., 2008, 
with collagen (Figure 4C), indicating that GIV and G protein interact 
exclusively with ligand-stimulated β1 integrins.
Taken together, we propose the following working model 
(Figure 4D): GIV is recruited to ECM-activated β1 integrins, followed 
by phosphorylation of GIV by FAK. Such phosphorylation is trig-
gered early during cell–ECM adhesion, a step in which GIV’s GEF 
function is dispensable, whereas both GIV’s phosphotyrosines and 
its GEF function are required during collagen-induced cell motility. 
When cell adhesion assays were carried out in the presence of 10% 
fetal bovine serum (FBS; as source of multiple growth factors), the 
importance of GIV’s GEF function during cell–ECM adhesion was 
observed, indicating that activation of Gαi by GIV may potentiate 
FA functions in a growth factor–dependent manner. Thus the GEF-
dependent enhancement of PI3K/Akt signaling we observe is likely 
to serve as a feedforward loop to enhance FAK activity, substrate 
(including GIV) phosphorylation, and cell adhesion/motility specifi-
cally in the presence of growth factors. The fact that the defects in 
cell adhesion/haptotaxis we observe in cells expressing a GEF-defi-
cient GIV mutant (FA) and those that express a nonphosphorylatable 
GIV mutant (YF) are not additive in cells in which both are combined 
(GIV-YF/FA; Figures 2, I and J, and 3B and Supplemental Figure 
S2D) favors the model that GIV’s GEF and phosphotyrosines work in 
a synergistic positive feedback loop.
GIV maintains FA integrity in multiple cancer cells, and its 
activation is enhanced during metastatic progression
Because both GIV and FAK facilitate cancer progression (Ghosh 
et al., 2011; Sulzmaier et al., 2014), next we examined the distribu-
tion and function of GIV in multiple cancer cells. Tyrosine-phosphor-
ylated GIV specifically localized to FAs across all cancer cell lines ex-
amined (Figure 5A and Supplemental Figure S4A). Depletion of GIV 
(by shRNA, ∼75-85% efficacy; Supplemental Figure S4, B–D) resulted 
in a decrease of FAs, as determined by a shift of vinculin (Figure 5A) 
and paxillin (Supplemental Figure S4A) from FAs to the cytosol, re-
duced FAK activity (Figure 5B), and impaired ECM-induced cell mo-
tility (Figure 5C and Supplemental Figure S4E), indicating that GIV is 
an essential functional component of FAs in multiple cancer cells. To 
determine how phosphorylation of GIV and its localization at FAs 
changes during cancer invasion/metastasis, we used a well-charac-
terized metastatic H2030 lung adenocarcinoma cell line and its cor-
responding highly metastatic subclone 3 (BrM3) that were selected 
in mice and display ∼10-fold enhanced ability to metastasize to the 
bones and brain (Nguyen et al., 2009). Tyrosine-phosphorylated GIV 
showed a heterogeneous staining pattern (intensity and distribution). 
Despite heterogeneity, tyrosine-phosphorylated GIV colocalized 
with vinculin-positive FAs exclusively in the BrM3 clone (Figure 5, 
D–F). These findings indicate that metastatic progression is associ-
ated with increased association of active pYGIV with FAs.
In conclusion, we have shown that GIV is both an enhancer and a 
substrate of FAK and a multimodular linker between multiple compo-
nents at FAs—for example, bundles of ECM-activated β1 integrins, 
the actin cytoskeleton, PI3-kinase/Akt, trimeric G protein, Gαi, and 
FAK. On the basis of our findings here that FAK and GIV-GEF cross-
potentiate each other, we propose that mechanochemical signal inte-
gration via the FAK-GIV axis is essential for the functional integrity of 
FAs and enhanced ECM-induced motility. Aberrant activation of this 
FAK-GIV axis during cancer metastasis may fuel cancer progression.
MATERIALS AND METHODS
Reagents and antibodies
Unless otherwise indicated, all reagents were of analytical grade and 
obtained from Sigma-Aldrich (St. Louis, MO). Cell culture media were 
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FIGURE 5: GIV is essential for the integrity of FAs and ECM-induced chemotaxis in metastatic cancer cells. Control (sh 
Control) or GIV-depleted (sh GIV) MDA MB-231 (left), Hs578T (middle), and HeLa (right) cells were fixed and stained for 
vinculin (A) or pYFAK (B) and analyzed by confocal microscopy. Bar, 25 μm. Depletion of GIV was confirmed by 
immunoblotting (Supplemental Figure S4, B–D). (C) Cell lines in A were analyzed for collagen-induced haptotactic cell 
motility using Transwell assays as in Figure 1H. Bar graphs show quantification of the number of migrating cells per 
high-power field (HPF). Data are presented as mean ± SEM; n = 3. Representative fields of the Transwell membrane are 
shown in Supplemental Figure S4E. *p < 0.05, ***p < 0.001. (D) Parental H2030 (left) and its corresponding metastatic 
BrM subclone (right) were fixed and stained for phospho–Y1764-GIV (pYGIV; red), vinculin (green), and DAPI (nuclei; 
blue) and analyzed by confocal microscopy. Representative fields are shown. Bar, 25 μm. (E) Bar graphs show 
quantification of the number of pYGIV-stained, vinculin-positive FA structures per cell in D (y-axis) determined using 
ImageJ. Error bars represent mean ± SD. ****p < 0.0001. (F) Immunoblotting of whole-cell lysates of cells in D showed 
similar levels of GIV, vinculin, and tubulin.
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2010; Garcia-Marcos et al., 2009). Briefly, bacterial cultures were 
induced overnight at 25°C with 1 mM isopropyl β-d-1-
thiogalactopyranoside (IPTG). Pelleted bacteria from 1 l of culture 
were resuspended in 10 ml of His lysis buffer (50 mM NaH2PO4, pH 
7.4, 300 mM NaCl, 10 mM imidazole, 1% [vol:vol] Triton X-100, 2× 
protease inhibitor cocktail [Complete EDTA-free, Roche Diagnos-
tics, Pleasanton, CA]). After sonication (3 × 30 s), lysates were centri-
fuged at 12,000 × g at 4°C for 20 min. Solubilized proteins were af-
finity purified on HisPur Cobalt Resin (Pierce, Rockford, IL). Proteins 
were eluted, dialyzed overnight against PBS, and stored at −80°C.
Whole-cell immunofluorescence
Cells were fixed at room temperature with 3% PFA in PBS for 25 min, 
treated with 0.1 M glycine for 10 min, and subsequently permeabi-
lized for 20 min (0.2% Triton X-100 in PBS) and blocked in PBS con-
taining 1% bovine serum albumin (BSA) and 0.1% Triton X-100 as 
described previously (Lopez-Sanchez et al., 2014). Primary and sec-
ondary antibodies where incubated for 1 h at room temperature in 
blocking buffer. In the case of total GIV (tGIV) immunofluorescence, 
cells were fixed using 100% methanol at −20 ºC for 10 min, followed 
by blocking buffer. ProLong (Life Technologies) was used as mount-
ing medium.
Dilutions of antibodies used were as follows: GIVcc, 1:250; phos-
pho–Tyr-1764-GIV, 1:300; vinculin, 1:400; paxillin, 1:200; integrin-β1, 
1:400; phalloidin, 1:1000; phospho-FAK, 1:100; DAPI, 1:2000; and 
secondary goat anti-rabbit (488), goat anti-mouse (594), and goat-
anti-mouse (635) Alexa-conjugated antibodies, 1:500.
Images were acquired at room temperature with a Leica TCS 
SPE-II with DMI4000 microscope equipped with a Leica Hamamatsu 
9100-02 camera and the LAS AF SPE software (Leica) using a 63× 
oil-immersion objective using 488-, 561-, 635-, and 405-nm laser 
lines for excitation. The settings were optimized and the final im-
ages scanned with line averaging of three scans. Quantification of 
focal adhesions was carried out using the particle analyzer applica-
tion on ImageJ (National Institutes of Health, Bethesda, MD) exactly 
as outlined previously (Horzum et al., 2015). All images were pro-
cessed using ImageJ software and assembled for presentation us-
ing Photoshop and Illustrator software (Adobe, San Jose, CA). Im-
ages shown are representative of 90–95% cells that were evaluated 
across three independent experiments.
In vitro kinase assay
These assays were performed using purified His-GIV CT proteins (∼5 
μg) and commercially obtained FAK kinase (SignalChem, Richmond, 
Canada) as previously described (Lin et al., 2011). Briefly, reactions 
were started by addition of 1000 μM ATP and carried out at 25°C for 
60 min in 30 μl of kinase buffer (60 mM HEPES, pH 7.5, 5 mM MgCl2, 
5 mM MnCl2, 3 μM Na3OV4). Reactions were stopped by addition of 
Laemmli sample buffer and boiling. Phosphorylated His-GIV-CT 
proteins were detected by immunoblotting.
In cellulo kinase assay
These assays were carried out exactly as outlined previously (Lin 
et al., 2011). Briefly, Cos7 cells coexpressing GIV-FLAG with either 
WT or kinase-dead mutant FAK kinase were pretreated with 0.1 μM 
Na3OV4 for 1 h before lysis. Lysates were separated by SDS–PAGE 
and analyzed by immunoblotting with anti-pYGIV antibody.
Generation of stable cell lines
shRNA control and shRNA GIV Cos7, HeLa, MDA-MB-231, and 
Hs578T stable cell lines using MissionRNAi technology (Sigma-Al-
drich) were generated by lentiviral transduction followed by selec-
tion with puromycin (2.5 μg/ml, except for Hs578T cells, for which it 
was 1 μg/ml). Depletion of endogenous GIV was confirmed by im-
munoblotting with GIV-CT rabbit antibody.
Lentiviral packaging was performed in HEK293T cells by cotrans-
fecting the shRNA constructs with psPAX2 and pMD2G plasmids 
(4:3:1 ratio, respectively), using Mirus LT1. The medium was changed 
after 24 h, and virus-containing medium was collected after 36–48 h 
and centrifuged and filtered through a 0.45-μm filter. psPAX2 and 
pMD2G plasmids were a generous gift from Christopher K. Glass 
(University of California, San Diego, La Jolla, CA).
shRNA GIV Cos7 stable cell lines expressing p3xFLAG-CMV-
14-GIV (GIV-3xFLAG) WT, FA, 2YF, and FA/2YF constructs were se-
lected as previously described (Garcia-Marcos et al., 2009; Lopez-
Sanchez et al., 2013) with the neomycin analogue G418 at 800 μg/
ml. Expression of various GIV constructs were confirmed to be simi-
lar to levels of endogenous GIV in shRNA control cells by immuno-
blotting with GIV-CT and FLAG antibodies.
Proximity ligation assay
In situ interaction of endogenous active GIV (identified by anti-
pTyr-1764) with active FAK (identified by anti-pTyr-397) was de-
tected using the proximity ligation assay kit Duolink (Olink Bio-
sciences, Uppsala, Sweden). Fixation, permeabilization, and 
blocking were done as described for whole-cell immunofluores-
cence. The PLA assay was performed according to the manufactur-
er’s recommendations. As negative control, cells incubated with 
only secondary antibodies were used.
Cell culture, transfection, lysis, and quantitative 
immunoblotting
Unless mentioned otherwise, cell lines used in this work were cul-
tured according to American Type Culture Collection (ATCC) guide-
lines or guidelines previously published for each line. H2030 paren-
tal and its brain metastatic (BrM3) counterpart were a generous gift 
from Joan Massagué (Memorial Sloan Kettering Cancer Center, 
New York, NY; Nguyen et al., 2009; Valiente et al., 2014). Cos7, 
HeLa, and Hs578T cells were obtained from ATCC.
Transfection, lysis, and immunoblotting were carried out exactly 
as described before (Ghosh et al., 2008, 2010). Cells were trans-
fected using Genejuice or Mirus LT1 following the manufacturers’ 
protocols. For assays involving serum starvation, serum concentra-
tion was reduced to 0% FBS overnight. Whole-cell lysates were pre-
pared after washing cells with cold PBS before resuspending and 
boiling them in sample buffer. Lysates used as a source of proteins in 
pull-down assays were prepared by resuspending cells in lysis buffer 
(20 mM HEPES, pH 7.2, 5 mM Mg acetate, 125 mM K acetate, 0.4% 
Triton X-100, and 1 mM dithiothreitol supplemented with sodium 
orthovanadate [500 μM], phosphatase [Sigma-Aldrich], and protease 
[Roche] inhibitor cocktails), after which they were passed through a 
28-gauge needle at 4°C and cleared (10,000 × g for 10 min) before 
use in subsequent experiments. For immunoblotting, protein sam-
ples were separated by SDS–PAGE and transferred to polyvinylidene 
fluoride membranes (Millipore). Membranes were blocked with PBS 
supplemented with 5% nonfat milk (or with 5% BSA when probing 
for phosphorylated proteins) before incubation with primary anti-
bodies. Infrared imaging with two-color detection and quantification 
were performed using a Li-Cor Odyssey imaging system. Dilution 
of primary antibodies used were as follows: anti–GIV-CT, 1:500; 
anti–phospho-Tyr-1764-GIV, 1:500; anti–phospho-Ser-473-Akt, 
1:250; anti-Akt, 1:500; anti-Gαi3, 1:333; anti-vinculin, 1:500; anti- 
paxillin, 1:500; anti-β tubulin, 1:1000; anti-myc, 1:250; anti-FLAG, 
1:250; anti-β1 integrin, 1:250; and anti–phospho-Tyr397-FAK, 
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1:250. All Odyssey images were processed using ImageJ software 
and assembled for presentation using Photoshop and Illustrator 
software.
Transwell migration assay
Cell migration was assessed using Costar Transwell inserts with 
8-μm pores in 24-well plates. The bottom sides of the membrane 
filters were coated with 50 μg/ml type I collagen at 4°C overnight, 
washed twice in PBS, and then blocked with 0.5% BSA for 2 h at 
37°C. Cells were detached using trypsin/EDTA and resuspended 
in DMEM supplemented with 0.4% FBS. A total of 5 × 104 cells 
was loaded in the upper well in a volume of 300 μl, and the lower 
well was filled with 750 μl of DMEM with 0.4% FBS. The plates 
were incubated at 37°C for the indicated periods of time before 
removing the remaining cell suspension. The migration insert was 
placed in a clean well containing 4% PFA for 1 h at room tempera-
ture, stained with Giemsa for 1 h, and washed three times in PBS. 
Cells on the upper side of the filters were removed with cotton-
tipped swabs, and the number of migrated cells on the bottom 
side of the filter was counted in five randomly chosen fields at 
200× magnification and averaged. All experiments were per-
formed in triplicate, and each experiment was repeated at least 
three times.
Colorimetric cell adhesion assay 96-well microtiter plates were 
coated with collagen, rinsed with PBS, and then blocked with 0.5% 
BSA for 1 h at 37°C. Cells were harvested with trypsin/EDTA, seeded 
in the wells at 2 × 104 cells/well in 50 μl of DMEM with 10 or 0.4% 
FBS, and allowed to adhere for 1 h at 37°C. Nonadherent cells were 
removed by gentle washing twice with PBS, and attached cells were 
fixed in 4% PFA for 15 min and then stained with 2.3% crystal violet 
(Sigma-Aldrich) for 10 min. Cells were extensively washed, air dried, 
and then lysed with 100 μl of 2% SDS. The absorbance of the wells 
was measured at 600 nm in a microplate reader. All experiments 
were performed in triplicate, and each experiment was repeated at 
least three times.
Immunoprecipitation
HeLa cell lysates (∼2 mg of protein) treated or not with collagen 
were incubated for 3 h at 4°C with 2 μg of anti–β1 integrin monoclo-
nal antibody or preimmune control mouse immunoglobulin G. Pro-
tein G–Sepharose beads (GE Healthcare, Wauwatosa, WI) were 
added and incubated at 4°C for an additional 60 min. Beads were 
washed, and bound immune complexes were eluted by boiling in 
nonreducing Laemmli sample buffer.
Data analysis and other methods
All experiments were repeated at least three times, and results were 
presented either as one representative experiment or as average ± 
SD. Statistical significance was assessed with the Student’s t test. 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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